

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BZCNLL95

Issuer Name

BELLEVUE HEALTHCARE TRUST PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights; An acquisition or disposal of financial instruments; An event changing the breakdown of voting rights

3. Details of person subject to the notification obligation

Name

Saba Capital Management, L.P.

City of registered office (if applicable)

New York

Country of registered office (if applicable)

United States

4. Details of the shareholder

Name	City of registered office	Country of registered office
Saba Capital Bluebird Fund, Ltd.		Cayman Islands
Saba Capital Income & Opportunities Fund		United States
Saba Capital CEF Opportunities 1, Ltd.		Cayman Islands
Saba Capital CEF Opportunities 2, Ltd.		Cayman Islands
Saba Capital Income & Opportunities Fund II		United States
Stone Ridge Archimedes Sub-Master (Red) LP		United States
I-94 Partners Fund LP		United States
Saba Capital Master Fund, Ltd.		Cayman Islands

5. Date on which the threshold was crossed or reached

06-Mar-2025

6. Date on which Issuer notified

07-Mar-2025

7. Total positions of person(s) subject to the notification obligation

	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	0.826109	10.650057	11.476166	27854689
Position of previous notification (if applicable)	0.679565	9.472307	10.151872	

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
GB00BZCNLL95	2005114	0	0.826109	0.000000
Sub Total 8.A	2005114		0.826109%	

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
Sub Total 8.B1				

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights
Total Return Swap	11/28/2025		Cash	25849575	10.650057
Sub Total 8.B2				25849575	10.650057%

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Boaz Weinstein	Saba Capital Management GP, LLC			
Saba Capital Management GP, LLC	Saba Capital Management, L.P.			11.476166%

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional Information

12. Date of Completion

07-Mar-2025

13. Place Of Completion

New York

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lse.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

HOLJRMPTTTMBRA